Pharmaceutical Executive August 28, 2025
Key Takeaways
- Boehringer Ingelheim prioritizes innovative therapies in high unmet medical need areas, reinvesting 28% of sales into R&D for breakthroughs in key therapeutic areas.
- Multidisciplinary teams and external collaborations are crucial for identifying novel targets and developing high-quality molecules, with 50% of the pipeline anchored in partnerships.
- Leadership emphasizes a patient-centric, purpose-driven approach, encouraging curiosity, strategic foresight, and resilience in navigating the evolving R&D landscape.
- Precision medicine and computational innovation, including AI and machine learning, are transforming drug discovery, requiring cross-functional collaboration and data-driven decision-making.
The Boehringer Ingelheim leader discusses his leadership style and how it impacts his team’s strategy.
Pharmaceutical Executive: What does it mean to lead a science-driven organization in the biopharma landscape?
Lamine...
Today's Sponsors
Today's Sponsor